中文 | English

Spotlight of R&D breakthrough on solid tumors in the digestive TA; a billion dollars market, are you ready?

Event details

DATE
Thursday November 19, 2020

VENUE
Online Webex / Gotomeeting

TIME
9am -10am (Berlin time)
4:00 PM - 5:00 PM (Beijing time)

RSVP
This is a complimentary event
VIP tickets priority for Lingmed current clients
Please RSVP by November 18, 2020
PRESENTERS
Lingling Cao, CEO & Founder
Dr Hank Wang, Medical advisor
Guest speaker

REGISTER
+86 21 5386 3003
BD@lingmed.net

Agenda

CET 9:00 - 9:30
  • Global and Chinese R&D of solid tumors of the digestive TA (e.g. pancreatic cancer)
  • GI solid tumor field licensing and M&A deals analysis
  • China market front runner in the field of solid tumor research
by Dr Hank Wang  (Chinese)
CET 9:30 - 9:35Linkedbio services & projects introductions    by Lingling Cao  (English)
CET 9:35 - 9:55Research Spotlight on a US biotech company innovation breakthrough by Guest speaker   (English)
CET 9:55 – 10:00Q&A (English & Chinese)

Presenters

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany

Hank Wang
Medical advisor
Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market

Download meeting reports
©Copyright 2013 - 2021 Lingmed Limited